267 related articles for article (PubMed ID: 32065848)
1. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
[TBL] [Abstract][Full Text] [Related]
2. Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.
Keller AM; Xiao Y; Peperzak V; Naik SH; Borst J
Blood; 2009 May; 113(21):5167-75. PubMed ID: 19279334
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.
Shin CA; Cho HW; Shin AR; Sohn HJ; Cho HI; Kim TG
Oncotarget; 2016 Jul; 7(29):46173-46186. PubMed ID: 27323820
[TBL] [Abstract][Full Text] [Related]
4. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
Oba T; Hoki T; Yamauchi T; Keler T; Marsh HC; Cao X; Ito F
J Immunol; 2020 Oct; 205(7):1867-1877. PubMed ID: 32848036
[TBL] [Abstract][Full Text] [Related]
5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
6. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.
Cho HI; Celis E
Cancer Res; 2009 Dec; 69(23):9012-9. PubMed ID: 19903852
[TBL] [Abstract][Full Text] [Related]
7. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
Powell KL; Stephens AS; Ralph SJ
Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
[TBL] [Abstract][Full Text] [Related]
8. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
9. Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses.
Kurche JS; Burchill MA; Sanchez PJ; Haluszczak C; Kedl RM
J Immunol; 2010 Aug; 185(4):2106-15. PubMed ID: 20639485
[TBL] [Abstract][Full Text] [Related]
10. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
11. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
[TBL] [Abstract][Full Text] [Related]
12. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
13. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
14. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
15. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
16. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity.
McWilliams JA; Sanchez PJ; Haluszczak C; Gapin L; Kedl RM
Vaccine; 2010 Feb; 28(6):1468-76. PubMed ID: 19995538
[TBL] [Abstract][Full Text] [Related]
17. An optimized peptide vaccine strategy capable of inducing multivalent CD8
Cho HI; Jung SH; Sohn HJ; Celis E; Kim TG
Oncoimmunology; 2015 Nov; 4(11):e1043504. PubMed ID: 26451316
[TBL] [Abstract][Full Text] [Related]
18. Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells.
Bak SP; Barnkob MS; Bai A; Higham EM; Wittrup KD; Chen J
J Immunol; 2012 Aug; 189(4):1708-16. PubMed ID: 22798683
[TBL] [Abstract][Full Text] [Related]
19. CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice.
Bathke B; Pätzold J; Kassub R; Giessel R; Lämmermann K; Hinterberger M; Brinkmann K; Chaplin P; Suter M; Hochrein H; Lauterbach H
Immunology; 2018 Jun; 154(2):285-297. PubMed ID: 29281850
[TBL] [Abstract][Full Text] [Related]
20. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
